Regencell Bioscience (NASDAQ:RGC) Shares Climb 7.6% – Time to Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price was up 7.6% on Monday. The company traded as high as $10.20 and last traded at $10.32. 165,426 shares changed hands during trading, a decline of 44% from the average session volume of 294,478 shares. The stock had previously closed at $9.59.

Wall Street Analyst Weigh In

RGC has been the topic of a number of recent research reports. Wall Street Zen cut Regencell Bioscience from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has a consensus rating of “Sell”.

Regencell Bioscience Trading Up 9.8%

The firm’s 50-day moving average price is $6.25 and its 200 day moving average price is $14.10.

Regencell Bioscience (NASDAQ:RGC) last posted its earnings results on Wednesday, October 7th. The company reported ($0.01) earnings per share for the quarter.

Institutional Trading of Regencell Bioscience

An institutional investor recently raised its stake in Regencell Bioscience stock. Bank of America Corp DE raised its stake in Regencell Bioscience Holdings Limited (NASDAQ:RGC) by 59,113.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,172 shares of the company’s stock after purchasing an additional 17,143 shares during the quarter. Bank of America Corp DE’s holdings in Regencell Bioscience were worth $437,000 as of its most recent filing with the Securities & Exchange Commission. 0.13% of the stock is owned by institutional investors and hedge funds.

About Regencell Bioscience

Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.

The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions.